Pexacerfont

Source: Wikipedia, the free encyclopedia.
Pexacerfont
Clinical data
Routes of
administration
Oral
ATC code
  • None
Legal status
Legal status
  • In general: uncontrolled
Identifiers
  • 8-(6-methoxy-2-methylpyridin-3-yl)-2,7-dimethyl-N-[(1R)-1-methylpropyl]pyrazolo[1,5-a]-1,3,5-triazin-4-amine
JSmol)
  • CC[C@@H](C)NC1=NC(=NC2=C(C(=NN21)C)C3=C(N=C(C=C3)OC)C)C
  • InChI=1S/C18H24N6O/c1-7-10(2)19-18-22-13(5)21-17-16(12(4)23-24(17)18)14-8-9-15(25-6)20-11(14)3/h8-10H,7H2,1-6H3,(H,19,21,22)/t10-/m1/s1 ☒N
  • Key:LBWQSAZEYIZZCE-SNVBAGLBSA-N ☒N
 ☒NcheckY (what is this?)  (verify)

Pexacerfont (

Bristol-Myers Squibb which acts as a CRF1
antagonist.

Corticotropin-releasing factor (CRF), also known as

stomach ulcers[citation needed], anxiety, depression, and development of high blood pressure and consequent cardiovascular problems.[2]

Pexacerfont is a recently developed CRF-1 antagonist which was in clinical trials for the treatment of anxiety disorders,[3] and has also been proposed to be useful for the treatment of depression and irritable bowel syndrome.[citation needed]

A recent multicenter, randomized, double-blind, placebo-controlled trial found that pexacerfont (100 mg/day) did not separate from placebo on the primary outcome measure (the mean change from baseline to end point in the

Hamilton Anxiety Scale score).[4]
These results suggest that blockade of CRF1 receptor may not be a feasible treatment for anxiety disorders in certain human populations.

See also

References

  1. ^ "International Nonproprietary Names for Pharmaceutical Substances (INN). RECOMMENDED International Nonproprietary Names: List 59" (PDF). World Health Organization. p. 60. Retrieved 16 July 2016.
  2. S2CID 7731338
    .
  3. ^ Clinical trial number NCT00481325 for "Study of Pexacerfont (BMS-562086) in the Treatment of Outpatients With Generalized Anxiety Disorder" at ClinicalTrials.gov
  4. S2CID 5370614
    .